Article
ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma
16 May 2023
Abstract excerpt
BACKGROUND: Cholangiocarcinoma (CHOL) is the second most common primary hepatic malignant tumor, following hepatocellular carcinoma (HCC). CHOL is highly aggressive and heterogeneous resulting in poor prognosis. The diagnosis and prognosis of CHOL has not improved in the past decade. Acyl-CoA synthetase long-chain family member 4 (ACSL4) is reported to be associated with tumors, however, its role in CHOL has not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
